

PATENT Customer Number 22,852 Attorney Docket No. 10142,0005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Evy LUNDGREN-AKERLUND	) Group Art Unit: 1644
Serial No.: 10/553,226	) Examiner: Maher M. Haddad
Filed: February 6, 2006	) ) Confirmation No.: 8983 ) )
For: MONOCLONAL ANTIBODY CAPABLE OF BINDING INTEGRIN ALPHA 10 BETA 1	
Commissioner for Patents P.O. Box 1450 Arlington, VA 22313-1450	
Sir:	·

## DECLARATION UNDER 37 C.F.R. § 1.801-1.809 REGARDING DEPOSIT OF BIOLOGICAL MATERIALS

I do hereby declare and state that:

1. On information and belief, the Applicant has, under the provisions of the Budapest Treaty, deposited viable cultures of a hybridoma cell line, on February 4, 2003, at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg 1b, D-38124 Braunschweig, Germany. The deposited hybridoma cell line produces a monoclonal antibody that binds to the extracellular I-domain of integrin alpha 10. The accession number for this deposit is DSM ACC2583. Copies of the International Form, Receipt of Original Deposit, and Viability Statement are attached to this Declaration.

Application No. 10/553,226 Attorney Docket No. 10142.0005

- 2. On information and belief, the cultures were deposited under conditions which insure that access to the cultures will be available to persons determined by the Commissioner to be entitled thereto under 37 C.F.R. § 1.14 and 35 U.S.C. § 122.
- 3. Upon issuance of a patent on the above-identified patent application, or continuation applications thereof, any restriction as to the public availability of the deposits will be irrevocably removed, and the deposits will be replaced should the depository be unable to distribute a sample upon a proper request, during the enforceable life of the patent, or the period of five years after the last public request for the deposits, whichever period is longer.
- 4. The undersigned further declares that all statements made herein on his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this document or any patent issuing thereon.

DATE: \_\_\_\_\_

Katarina Dahlenborg

Cartela AB